Filtered By:
Condition: Bleeding
Countries: Japan Health
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 236 results found since Jan 2013.
Edoxaban vs. Vitamin K Antagonist for Atrial Fibrillation After Transcatheter Aortic Valve Replacement in Japanese Patients - A Subanalysis of the ENVISAGE-TAVI AF Trial
CONCLUSIONS: In Japanese patients with AF after successful TAVR, edoxaban and VKA treatment have similar safety and efficacy profiles.PMID:35965066 | DOI:10.1253/circj.CJ-22-0093
Source: Circulation Journal - August 14, 2022 Category: Cardiology Authors: Yusuke Watanabe Kentaro Hayashida Masanori Yamamoto Futoshi Yamanaka Kazumasa Yamasaki Toru Naganuma Yohei Ohno Masahiro Yamawaki Nobuyuki Morioka Kazuki Mizutani Norio Tada Hiroshi Ueno Hidetaka Nishina Masaki Izumo Yoshifumi Nakajima Kenji Ando Kensuke Source Type: research
Comparison of short-term clinical outcomes between low-dose prasugrel and clopidogrel as part of triple antithrombotic therapy in patients requiring oral anticoagulant therapy and percutaneous coronary intervention
ConclusionsCombination of low-dose prasugrel and DOAC was associated with lower incidence of MI, ischemic stroke, and blood transfusion. Low-dose prasugrel may be feasible as part of triple therapy in patients undergoing PCI.
Source: PLoS One - July 28, 2022 Category: Biomedical Science Authors: Hideki Kitahara Source Type: research
Effect of Polypharmacy on Clinical Outcomes in Elderly Patients With Non-Valvular Atrial Fibrillation - A Sub-Analysis of the ANAFIE Registry
CONCLUSIONS: Polypharmacy was frequent among elderly patients with NVAF who were older with more comorbidities, and was independently associated with a higher incidence of extracranial events.PMID:35858804 | DOI:10.1253/circj.CJ-22-0170
Source: Circulation Journal - July 20, 2022 Category: Cardiology Authors: Takeshi Yamashita Masaharu Akao Hirotsugu Atarashi Takanori Ikeda Yukihiro Koretsune Ken Okumura Wataru Shimizu Shinya Suzuki Hiroyuki Tsutsui Kazunori Toyoda Atsushi Hirayama Masahiro Yasaka Takenori Yamaguchi Satoshi Teramukai Tetsuya Kimura Yoshiyuki M Source Type: research
Clinical Characteristics of Non-Valvular Atrial Fibrillation Patients With a Large Left Atrial Appendage Ostium-Limiting Percutaneous Closure
CONCLUSIONS: NVAF patients with a large LAA ostium may have a higher risk of stroke and bleeding. LSAF and factors leading to LA overload may be closely associated with LAA ostial dilatation and can promote it.PMID:35786689 | DOI:10.1253/circj.CJ-22-0053
Source: Circulation Journal - July 5, 2022 Category: Cardiology Authors: Tomoko Machino-Ohtsuka Daishi Nakagawa Noor K Albakaa Tomofumi Nakatsukasa Naoto Kawamatsu Kimi Sato Masayoshi Yamamoto Hiro Yamasaki Tomoko Ishizu Masaki Ieda Source Type: research
Treatment strategy of dabigatran etexilate following the availability of idarucizumab in Japanese patients with non-valvular atrial fibrillation: J-Dabigatran Surveillance 2
CONCLUSIONS: Dabigatran continues to be safe and well tolerated in patients with NVAF for stroke and systemic embolism prevention and continues to be prescribed appropriately. Treatment outcomes have not changed since the availability of idarucizumab. Since the J-Dabi1 study, treatment guidelines for anticoagulation use in NVAF have been updated based on emerging clinical evidence, accounting for differences in patient characteristics, and making dabigatran a preference for distinct patient populations.PMID:35717283 | DOI:10.1016/j.jjcc.2022.04.007
Source: Journal of Cardiology - June 18, 2022 Category: Cardiology Authors: Takeshi Yamashita Shinichiro Uchiyama Hirotsugu Atarashi Ken Okumura Yukihiro Koretsune Masahiro Yasaka Junichi Wakayama Taku Fukaya Hiroshi Inoue J-Dabigatran Surveillance Investigators Source Type: research
Recurrent and Multiple Intracerebral Hemorrhages in Polycythemia Vera Secondary to Myelofibrosis: A Case Report and Literature Review
Polycythemia vera (PV) is one of the myeloproliferative neoplasms and has higher frequency of theJAK2 V617F mutation. Hemorrhagic stroke is rare in PV, and myelofibrosis is secondary to PV. A 76-year-old Japanese man was diagnosed as PV with theJAK2 V617F mutation at the age of 63 years. He developed anemia together with secondary myelofibrosis, and then 40 mg ruxolitinib was started at 70 years. At 76 years, he presented with apathy and was diagnosed with intracerebral hemorrhage (ICH) in the right thalamus. Six months later, he developed multiple ICHs in bilateral cerebellar hemispheres. Leukocyte count was 57,600/ μL, ...
Source: Case Reports in Neurology - June 7, 2022 Category: Neurology Source Type: research
Trends of anticoagulant use and outcomes of patients with non-valvular atrial fibrillation: Findings from the RAFFINE registry
CONCLUSIONS: The all-cause mortality, cardiovascular mortality, and incidence of major bleeding events were higher in the warfarin group than in the DOAC group. After adjustment, warfarin use was not associated with an increase in these events. Off-label dosing of DOACs is not rare and is not associated with reduced effectiveness. The impact of off-label dosing of each DOAC on clinical events should be assessed using a larger population.PMID:35346556 | DOI:10.1016/j.jjcc.2022.03.006
Source: Journal of Cardiology - March 29, 2022 Category: Cardiology Authors: Sakiko Miyazaki Katsumi Miyauchi Hidemori Hayashi Kazuo Yamashiro Ryota Tanaka Yuji Nishizaki Shuko Nojiri Satoru Suwa Masataka Sumiyoshi Yuji Nakazato Takao Urabe Nobutaka Hattori Tohru Minamino Hiroyuki Daida Source Type: research
